Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
about
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesMinnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
P2860
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Frontline treatment with gemci ...... ncology Research Group (HORG).
@ast
Frontline treatment with gemci ...... ncology Research Group (HORG).
@en
type
label
Frontline treatment with gemci ...... ncology Research Group (HORG).
@ast
Frontline treatment with gemci ...... ncology Research Group (HORG).
@en
prefLabel
Frontline treatment with gemci ...... ncology Research Group (HORG).
@ast
Frontline treatment with gemci ...... ncology Research Group (HORG).
@en
P2093
P2860
P1476
Frontline treatment with gemci ...... ncology Research Group (HORG).
@en
P2093
A Christopoulou
A Kotsakis
D Hatzidaki
E Kontopodis
E Stathopoulos
J Souglakos
K Kalbakis
N Kentepozidis
O Katopodis
P2860
P2888
P304
P356
10.1007/S00280-014-2509-6
P577
2014-06-15T00:00:00Z
P6179
1038547031